Modality
Cell Therapy
MOA
AuroraAi
Target
HER2
Pathway
RAS/MAPK
ThymomaMyelofibrosis
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
Jun 2017
→ Mar 2031
Phase 2Current
NCT07393915
526 pts·Thymoma
2018-01→2031-03·Not yet recruiting
NCT06824990
871 pts·Thymoma
2017-06→2031-01·Terminated
1,397 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-01-224.8y awayPh2 Data· Thymoma
2031-03-074.9y awayPh2 Data· Thymoma
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Termina…
P2
Not yet…
Catalysts
Ph2 Data
2031-01-22 · 4.8y away
Thymoma
Ph2 Data
2031-03-07 · 4.9y away
Thymoma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07393915 | Phase 2 | Thymoma | Not yet recr... | 526 | LiverFat |
| NCT06824990 | Phase 2 | Thymoma | Terminated | 871 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |